Rob Dillard

DocwireNews

Four-year follow-up data from the HIMALAYA trial showed that single tremelimumab regular interval durvalumab (STRIDE) improved overall survival (OS) and demonstrated a durable long-term survival benefit in patients with unresectable hepatocellular carcinoma (uHCC). The study was presented at the Symposium on Clinical Interventional Oncology 2023.
In this analysis, 1171 patients were randomized to STRIDE (n=393), durvalumab (n=389), or sorafenib (n=389). OS and serious treatment-related adverse events (TRAEs) were the main study outcomes.
The estimated 36-month OS rates for STRIDE were 30.7% compared with 19.8% for sorafenib, which was consistent with the primary analysis. At 48 months, the OS rate remained higher for STRIDE (25.2%) versus sorafenib (15.1%), the researchers noted. They observed that TRAEs occurred in 17.5% of participants treated with STRIDE and 9.6% of participants treated with sorafenib, with no new events occurring after the primary analysis for STRIDE.
“These data reinforce the sustained, long-term OS benefit of STRIDE versus sorafenib in a diverse uHCC population, demonstrating unprecedented 3- and 4-year OS rates and [the] longest follow-up to date in phase 3 uHCC studies. STRIDE maintained a tolerable safety profile, with no new serious safety events,” the researchers concluded.

Emily Menendez

Non-Invasive NETseq Classifier Determines NET Diagnosis With High Accuracy, Sensitivity

GEP-NETs

High Tumor Mutational Burden Linked to Worse OS, RFS in Patients with HCC

Hepatocellular Carcinoma

Cecilia Brown

IASLC and LCRF Award Team Science Grant for Work on Immune-Based Approaches to Target Drug-Resistant Lung Cancer Cells

Lung Cancer

Latest News

Long-term Survival Observed in HIMALAYA Study of Durvalumab Plus Tremelimumab for uHCC

Unresectable HCC

Durvalumab plus tremelimumab significantly improved overall survival in patients with unresectable liver cancer.

Assessing the Efficacy of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe